EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has entered a purchase and marketing agreement with Vantage Outsourcing for its ophthalmic product DEXYCU®, enabling broader access in over 25 states. This collaboration aims to integrate DEXYCU into surgical protocols for treating ocular inflammation related to cataract surgery. President Nancy Lurker emphasizes the partnership's potential for expanding their reach within the cataract surgery market. Vantage Outsourcing's services will enhance the postoperative experience for patients by providing a long-lasting anti-inflammatory treatment.

Positive

• New agreement with Vantage Outsourcing to promote DEXYCU in 25+ states.
• Potential for increased market penetration in the cataract surgery sector.
• Partnership aligns with EyePoint's strategy to enhance DEXYCU's availability.

Negative

• None.

WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® (dexamethasone intraocular suspension) 9%. Vantage Outsourcing is a leading cataract surgical service provider to a variety of hospitals, ambulatory surgery centers (ASCs), and physicians. The agreement will enable customers in the Vantage Outsourcing network, which spans over a 25+ state service area, to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

“We are fortunate to partner with Vantage Outsourcing, as we continue to expand our growing lists of ASCs and integrated healthcare networks in the U.S. that can make DEXYCU available to their cataract surgery patients. Vantage Outsourcing represents a unique opportunity to increase our presence with cataract surgery customers that had previously been beyond our reach, and we believe Vantage Outsourcing is an ideal partner due to our shared commitment to patient care,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “This important partnership aligns with our greater strategic approach of making DEXYCU more widely available to key ASCs and their patients in select U.S. regions.”

“We are excited to partner with EyePoint in bringing innovative, high quality products to our surgeons and their patients,” said Ann Deters, Chief Executive Officer of Vantage Outsourcing. “Being able to add DEXYCU to our product service line will allow us to greatly improve the patient’s postoperative experience due to DEXYCU’s long-lasting anti-inflammatory activity and single administration.”

About Vantage
Vantage’s business is a shared-surgical service for hospitals, surgery centers and ophthalmologists. Vantage's technical staff bringing equipment, surgical supplies, implants, micro-instruments, as well as technical expertise, to the operating room suite. This innovative model allows facilities to increase surgery revenue, avoid capital equipment risks, increase surgical efficiencies, and convert fixed costs to variable costs, as it relates to surgical procedures.

About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF therapy initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the extent to which our business could be adversely impacted by the effects of the COVID-19 coronavirus pandemic, as well as the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a vital, novel six-month treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreement with Equinox Science; termination or breach of current license agreements, including our agreement with Equinox Science; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contacts
Investors:
Argot Partners
Sam Martin or Joe Rayne
212-600-1902
eyepoint@argotpartners.com   

Media:
Thomas Gibson
201-476-0322
tom@tomgibsoncommunications.com     

FAQ

What is the recent agreement EyePoint Pharmaceuticals made regarding DEXYCU?

EyePoint Pharmaceuticals entered a purchase and marketing agreement with Vantage Outsourcing to include DEXYCU in surgical protocols for cataract surgery.

How will the agreement with Vantage Outsourcing benefit EyePoint Pharmaceuticals?

The agreement is expected to expand EyePoint's reach in the cataract surgery market, improving patient access to DEXYCU.

What is DEXYCU and its purpose?

DEXYCU is a dexamethasone intraocular suspension used to treat postoperative inflammation following cataract surgery.

What is the significance of the partnership with Vantage Outsourcing?

The partnership provides an opportunity for EyePoint to increase its presence in healthcare networks, enhancing the availability of DEXYCU.

In how many states does Vantage Outsourcing operate?

Vantage Outsourcing operates in over 25 states, providing a wide reach for DEXYCU.